Efficiency of the therapy of menstrual cycle disturbances and obesity at patients with the metabolic syndrome

Carried out research has shown normalization of rhythm and duration of menses and also depression of body mass at patients with a metabolic syndrome as a result of treatment by dysmenorm and sibutramine. Average depression of body mass for the period of treatment has made 15% from initial size. At the ma-jority of patients depression of body mass has reached clinically significant sizes. To the end of research 50% of patients reached depression of body mass more than 5% from initial size. Body mass at 40% of patients has decreased on 10% and more from initial, and only at 10% - less than 5%.